Company Cyber Security Posture
NANA
NA Company Details
NA
NA
NA
NA
NA
NA
Scan still pending
NA
NA
NA Risk Score (AI oriented)Between 200 and 800
This score is AI-generated and less favored by cyber insurers, who prefer the TPRM score.
NA Global Score.png)
Company Scoring based on AI Models
| Model Name | Date | Description | Current Score Difference | Score |
|---|---|---|---|---|
| AVERAGE-Industry | 03-12-2025 | This score represents the average cybersecurity rating of companies already scanned within the same industry. It provides a benchmark to compare an individual company's security posture against its industry peers. | N/A | Between 200 and 800 |
Company Cyber Security News & History
| Entity | Type | Severity | Impact | Seen | Url ID | Details | View |
|---|
Company Subsidiaries
NA
Access Data Using Our API
Get company history
Rapid.png)
NA Cyber Security News
Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple
In this article, we are going to take a look at where Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands against other stocks under $10 that will triple.
Transcript : Intellia Therapeutics, Inc., Q1 2025 Earnings Call, May 08, 2025
Presentation Operator Message Operator (Operator). Good morning and welcome to the Intellia First Quarter 2025 Financial Results Conference ...
7 Top Gene-Editing Stocks to Buy | Investing
7 Top Gene-Editing Stocks to Buy · Eli Lilly & Co. (LLY) · Sanofi (SNY). Sanofi is a French pharmaceutical company that specializes in atopic ...
Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy?
We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Intellia ...
Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average
Intellia Therapeutics, Inc. (NTLA) is looking like an interesting pick from a technical perspective, as the company reached a key level of ...
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 12.70% and 14.67%, respectively, for the quarter ended March 2025.
Intellia Therapeutics Inc (NTLA) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ...
Intellia Therapeutics Inc (NTLA) showcases clinical progress and financial strategy despite a drop in collaboration revenue and cash ...
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline
Wall Street expects a year-over-year decline in earnings on lower revenues when Intellia Therapeutics, Inc. (NTLA) reports results for the ...
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
NA Similar Companies
Genentech
About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions s
MilliporeSigma
Together with our colleagues, customers and stakeholders, we impact life and health with science. Before researchers can make scientific breakthroughs, they must have access to state-of-the-art tools, services and expertise to perform experiments and engineer new products. That’s where we come in.
Syneos Health
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals w
Gilead Sciences
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy healt
Agilent Technologies
Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product
Eurofins
Since 1987, Eurofins has grown from one laboratory in Nantes, France to ca. 63,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to eval
Frequently Asked Questions
Explore insights on cybersecurity incidents, risk posture, and Rankiteo's assessments.
NA CyberSecurity History Information
How many cyber incidents has NA faced?
Total Incidents: According to Rankiteo, NA has faced 0 incidents in the past.
What types of cybersecurity incidents have occurred at NA?
Incident Types: The types of cybersecurity incidents that have occurred include .
Additional Questions
What Do We Measure?
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
These are some of the factors we use to calculate the overall score:
Identify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.
Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.
Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.
Leverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.
